Wealth Enhancement Advisory Services
HRTX icon

Wealth Enhancement Advisory Services’s Heron Therapeutics HRTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
32,397
+15,793
+95% +$12.7K ﹤0.01% 4081
2026
Q1 		$13.3K Buy
+16,604
New +$19.2K ﹤0.01% 3537
2025
Q4 		– Sell
-25,577
Closed -$33.8K – 3715
2025
Q3 		$33.8K Sell
25,577
-11,551
-31% -$18.3K ﹤0.01% 3463
2025
Q2 		$81.7K Buy
37,128
+1,512
+4% +$3.09K ﹤0.01% 3169
2025
Q1 		$78.4K Buy
35,616
+482
+1% +$935 ﹤0.01% 2806
2024
Q4 		$53.8K Sell
35,134
-10,139
-22% -$16.4K ﹤0.01% 2860
2024
Q3 		$90.1K Buy
45,273
+7,927
+21% +$18.9K ﹤0.01% 2575
2024
Q2 		$131K Buy
37,346
+1,366
+4% +$4.2K ﹤0.01% 2368
2024
Q1 		$99.7K Buy
35,980
+9
+0% +$23 ﹤0.01% 2295
2023
Q4 		$61.2K Sell
35,971
-1,640
-4% -$1.81K ﹤0.01% 2205
2023
Q3 		$38.7K Buy
+37,611
New +$53.5K ﹤0.01% 2171

Other funds holding HRTX

CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
AR
Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
TWM
TopTier Wealth Management Muskego, Wisconsin $166M AUM
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Wealth Enhancement Advisory Services's HRTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Heron Therapeutics (HRTX) stake by 95% in Q2 2026, buying an estimated $12.7K and bringing the position to 32,397 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4081.

Wealth Enhancement Advisory Services first reported a position in HRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $131K in Q2 2024. 11 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 32,397 shares of Heron Therapeutics worth $13.4K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 15,793 Heron Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Heron Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4081 holding.
  • Wealth Enhancement Advisory Services first reported a position in Heron Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Wealth Enhancement Advisory Services's Heron Therapeutics position peaked at $131K in Q2 2024.
  • 11 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.